Graphical Research.jpg
Microsurgery Robot Market Trends 2021 | North America, Europe, & APAC Industry Forecasts 2027: Graphical Research
25 févr. 2021 05h00 HE | Graphical Research
Pune, India, Feb. 25, 2021 (GLOBE NEWSWIRE) -- The microsurgery robot market demand is expected to witness an uptick throughout the world as robotic surgeries allow surgeons to perform numerous...
Graphical Research.jpg
Fitness Equipment Market Trends | North America, Europe, & APAC Industry Statistics 2020-2026: Graphical Research
18 févr. 2021 07h00 HE | Graphical Research
Pune, India, Feb. 18, 2021 (GLOBE NEWSWIRE) -- The fitness equipment market is predicted to expand at a substantial CAGR during the forecast period. With the rising emphasis on improving the...
InCarda Logo.png
InCarda Therapeutics Announces Enrollment of First U.S. Patient in Phase 2 INSTANT Trial of InRhythm™ for Treatment of Atrial Fibrillation
19 janv. 2021 08h05 HE | InCarda Therapeutics, Inc.
SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for...
CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing
05 janv. 2021 10h55 HE | CVRx, Inc.
MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that it is expanding...
ResearchDriveLogo.jpg
The Necessity to Develop a Vaccine Against Covid-19 to Enhance the Computer Aided Drug Discovery Market in Covid-19 Pandemic – Exclusive Report [120 Pages] by Research Dive
07 déc. 2020 09h00 HE | Research Dive
New York, USA, Dec. 07, 2020 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the computer aided drug discovery market is estimated to rise to $5,427.2 billion by 2026, from a...
CVRx® BAROSTIM Therapy Receives CMS Approval for Transitional Pass-Through Payment Status
03 déc. 2020 11h54 HE | CVRx, Inc.
MINNEAPOLIS, Dec. 03, 2020 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that the Centers for...
FBI LOGO TM.png
Global Cardiovascular Devices Market to Rise at 6.4% CAGR and Reach USD 82.20 Billion by 2026; Rising Awareness and Increasing Demand for Cardiovascular Surgical Devices Will Promote Market Growth, says Fortune Business Insights™
26 nov. 2020 05h17 HE | Fortune Business Insights
Pune, Nov. 26, 2020 (GLOBE NEWSWIRE) -- According to the report, the cardiovascular devices market size was USD 49.90 billion in 2018 and is projected to rise at a CAGR of 6.4% between 2019 and...
US Capital Global Securities Launches $10MM Convertible Preferred Stock Offering for Cardax, Inc.
24 nov. 2020 16h58 HE | US Capital Global
San Francisco, California, Nov. 24, 2020 (GLOBE NEWSWIRE) -- US Capital Global Securities LLC, an affiliate of US Capital Global, is offering to eligible investors an investment opportunity of up to...
CVRx® Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts
18 nov. 2020 14h56 HE | CVRx, Inc.
MINNEAPOLIS, Nov. 18, 2020 (GLOBE NEWSWIRE) -- CVRx, Inc., developer of FDA-approved Barostim Therapy to treat chronic heart failure (HF), announced a CFO transition as part of the company’s...
InCarda Logo.png
InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythm™ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 2020
13 nov. 2020 10h00 HE | InCarda Therapeutics, Inc.
Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Study Findings Provide Proof of Concept for First-of-its-Kind Inhaled Antiarrhythmic for Treatment of...